Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Sohal on Eligibility of Patients with Pancreatic Cancer for Clinical Trials

July 4th 2019

Davendra Sohal, MD, MPH, discusses the SWOG S1505 trial, which looks at initial findings on eligibility and neoadjuvant chemotherapy experience with mFOLFIRINOX versus gemcitabine/nab-paclitaxel for resectable pancreatic adenocarcinoma.

Published Data Back Regorafenib Dose Escalation in Colorectal Cancer

July 3rd 2019

A weekly regorafenib (Stivarga) dose-escalation strategy beginning at 80 mg and ending at 160 mg is an appropriate and potentially optimal approach for previously treated patients with metastatic colorectal cancer.

Napabucasin Phase III Trial Discontinued in Pancreatic Cancer

July 3rd 2019

The CanStem111P trial, which was evaluating the combination of napabucasin, weekly nab-paclitaxel (Abraxane), and gemcitabine compared with nab-paclitaxel/gemcitabine alone in patients with metastatic pancreatic ductal adenocarcinoma, will be discontinued due to futility.

Dr. Lieu on Investigational Immunotherapy Strategies in mCRC

July 2nd 2019

Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associate director for clinical research, at the University of Colorado Cancer Center, discusses investigational immunotherapy strategies in metastatic colorectal cancer (mCRC).

Genome Sequencing Studies Shake Up Views on the Cancer Mutation Landscape

July 2nd 2019

Emerging findings from the most expansive studies of tumor genomes ever conducted are building a case for integrating all aspects of germline and somatic mutations into the analytical paradigm as a logical next step for precision oncology.

Dr. Hochster on SWOG S1513 Results in Pancreatic Cancer

June 26th 2019

Howard Hochster, MD, FACP, discusses results from the SWOG S1513 study, which examined the use of second-line modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) versus solely FOLFIRI in metastatic pancreatic cancer.

FDA Approves Newly Designed Syringe for Lanreotide in GEP-NETs

June 25th 2019

The FDA has granted an approval to a prefilled syringe for lanreotide (Somatuline Depot), which has been designed to enable healthcare providers to administer the injection easier, for the treatment of adults with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors.

Dr. Davis on Caveats of the KEYNOTE-062 Trial Findings in Gastric/GEJ Cancer

June 25th 2019

S. Lindsey Davis, MD, an assistant professor of medicine and gastrointestinal medical oncologist at the University of Colorado Cancer Center, discusses caveats of the phase III KEYNOTE-062 trial findings in gastric and gastroesophageal junction (GEJ) cancer.

TAS-102 Continues to Demonstrate Efficacy, Safety in CRC and Gastric Cancers

June 24th 2019

Howard S. Hochster, MD, provides insight into TAS-102 (trifluridine/tipiracil; Lonsurf) and highlights other important research being conducted in the colorectal cancer space.

Study Sheds Light on Incidence Patterns of Early-Onset CRC

June 24th 2019

Ana Acuna-Villaorduna, MD, provides further insight into the study that compares age and race as factors for the incidence of early-onset colorectal cancer.

Frontline Nivolumab Misses OS Endpoint in Unresectable HCC

June 24th 2019

Nivolumab (Opdivo) did not achieve statistical significance for improved overall survival compared with sorafenib (Nexavar) as a frontline therapy for patients with unresectable hepatocellular carcinoma as per a prespecified analysis, missing the primary endpoint of the phase III CheckMate-459 trial.

Dr. Cohn on Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer

June 22nd 2019

Allen L. Cohn, MD, medical oncologist, Rocky Mountain Cancer Centers, discusses the use of neoadjuvant chemotherapy in the treatment of patients with locally advanced pancreatic cancer.

Dr. Acuna-Villaorduna on the Increase of Early-Onset CRC Diagnoses

June 21st 2019

Ana Acuna-Villaorduna, MD, Heme/Oncology fellow at Montefiore Medical Center/Albert Einstein College of Medicine, discusses the increase of early-onset colorectal cancer, specifically in African-American and Hispanic populations.

Dr. El-Khoueiry on the Role of Ramucirumab in Advanced HCC

June 20th 2019

Anthony B. El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, discusses the role of ramucirumab in advanced hepatocellular carcinoma.

Expanding the Use of Immunoscore in Early-Stage CRC

June 20th 2019

Jerome Galon, PhD, research director, French Institute of Health and Medical Research, discusses ways to expand the use of Immunoscore in early-stage colorectal cancer.

Increased Incidence Drives Novel Approaches Across Pancreatic Cancer Settings

June 20th 2019

Allen L. Cohn, MD, discusses how the increased incidence of pancreatic cancer has spurred an abundance of novel treatment approaches to combat the disease.

Dr. Philip Discusses the Use of Lutathera in NETs

June 19th 2019

Philip A. Philip, MD, PhD, FRCP, professor of Medicine, Wayne State University School of Medicine, clinical professor of Oncology at Barbara Ann Karmanos Cancer Institute, discusses the use of Lutathera in neuroendocrine tumors.

Dr. Lenz on Next Steps With Immunotherapy in mCRC

June 19th 2019

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses next steps with immunotherapy in metastatic colorectal cancer.

Novel Combos, Predictive Biomarkers Slated as Future of HCC Treatment

June 19th 2019

Anthony B. El-Khoueiry, MD, provides insight on the rapidly evolving treatment options in hepatocellular carcinoma.

Dr. Nallapareddy on the Use of ctDNA Testing in Colorectal Cancer

June 19th 2019

Sujatha Nallapareddy, MD, gastrointestinal medical oncologist at Rocky Mountain Cancer Centers, discusses the use of circulating tumor DNA (ctDNA) testing in patients with colorectal cancer (CRC).